CBP - Pioneering and developing Bi-targeting XDC technology
Pioneering and developing Bi-targeting XDC technology
CBP-1019-102
CBP-1019-102
A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Bi-Ligand-Drug Conjugate CBP-1019 in Patients with Advanced Thoracic Tumors.